Kang Stem Biotech Overview
- Founded
-
2010
- Status
-
Public
- Employees
-
113
- Stock Symbol
-
217730
- Share Price
-
$2.42
- (As of Wednesday Closing)
Kang Stem Biotech General Information
Description
Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Stock Exchange
KRX
Primary Office
- 17th Floor, Shinan Building
- 512 Teheran-ro, Gangnam-gu
- Seoul
- South Korea
+82 00-000-0000
Kang Stem Biotech Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.42 | $2.36 | $1.74 - $3.27 | $91.8M | 37.9M | 157K | -$0.41 |
Kang Stem Biotech Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 66,093 | 66,093 | 66,788 | 159,473 |
| Revenue | 12,615 | 12,615 | 10,830 | 7,739 |
| EBITDA | (13,003) | (13,003) | (15,643) | (14,462) |
| Net Income | (15,661) | (15,661) | (18,638) | (15,644) |
| Total Assets | 63,814 | 63,814 | 86,677 | 75,629 |
| Total Debt | 10,586 | 10,586 | 11,801 | 11,945 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kang Stem Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kang Stem Biotech Patents
Kang Stem Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021365476-A1 | Method for construction of atopic dermatitis model by using pluripotent stem cell-derived skin organoid | Pending | 21-Oct-2021 | ||
| AU-2021321833-A1 | Method for producing highly functional artificial organs using aptamers | Pending | 06-Aug-2020 | ||
| JP-2023511965-A | Off-the-shelf stem cells and immune cells and pharmaceutical compositions containing same | Pending | 23-Jan-2020 | 0000000000 | |
| EP-4183868-A1 | Off-the-shelf stem cells and immune cells, and pharmaceutical composition comprising same | Pending | 23-Jan-2020 | 0000000000 | |
| US-20210254005-A1 | Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same | Pending | 23-Jan-2020 | C12N5/0606 | 0 |
Kang Stem Biotech Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Na Jong-cheon | Chief Executive Officer | ||
| Kang Kyung-sun | Founder | ||
| Chang-kyu Choi | Senior Vice President |
Kang Stem Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kang Stem Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|